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ABSTRACT
Tumor budding in colorectal cancer is likened to an epithelial-mesenchymal 
transition (EMT) characterized predominantly by loss of E-cadherin and up-regulation 
of E-cadherin repressors like TWIST1 and TWIST2. Here we investigate a possible 
epigenetic link between TWIST proteins and the tumor budding phenotype. TWIST1 
and TWIST2 promoter methylation and protein expression were investigated in six 
cell lines and further correlated with tumor budding in patient cohort 1 (n = 185). 
Patient cohort 2 (n = 112) was used to assess prognostic effects. Laser capture 
microdissection (LCM) of tumor epithelium and stroma from low- and high-grade 
budding cancers was performed. In colorectal cancers, TWIST1 and TWIST2 expression 
was essentially restricted to stromal cells. LCM results of a high-grade budding case 
show positive TWIST1 and TWIST2 stroma and no methylation, while the low-grade 
budding case was characterized by negative stroma and strong hypermethylation. 
TWIST1 stromal cell staining was associated with adverse features like more advanced  
pT (p = 0.0044), lymph node metastasis (p = 0.0301), lymphatic vessel invasion 
(p = 0.0373), perineural invasion (p = 0.0109) and worse overall survival time 
(p = 0.0226). Stromal cells may influence tumor budding in colorectal cancers through 
expression of TWIST1. Hypermethylation of the tumor stroma may represent an 
alternative mechanism for regulation of TWIST1.
INTRODUCTION
Epithelial-mesenchymal transition (EMT) in cancer 
refers to a reversible and dynamic process by which cells 
tend to lose epithelial characteristics in favor of a more 
mesenchymal phenotype [1]. This includes on the one-
hand de-differentiation and loss of cell adhesion, while on 
the other resistance to apoptosis and a gain in migration 
and invasion potential.
Central to this process is E-cadherin, a cell-cell 
adhesion molecule that provides an anchor between the 
basolateral membrane of adherens junctions and the actin 
cytoskeleton [2]. Loss of E-cadherin is considered a pre-
requisite for EMT favoring tumor cell dissemination and 
metastasis [3]. Although mutation of the E-cadherin gene 
(CDH1) and CpG island hypermethylation of the CDH1 
promoter have been described, E-cadherin may also be 
inhibited through transcriptional repression by other 
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factors such as ZEB family members and the TWIST-
family of bHLH proteins [4–10]. TWIST itself may 
be regulated through gene promoter hypermethylation 
leading to absence of the protein in HCT116 cells [11]. 
Moreover, epigenetic regulation also impacts microRNAs 
that regulate gene networks involved in EMT [12].
In colorectal cancers, loss of membranous 
E-cadherin is frequently observed along the tumor invasion 
front, most notably in tumor budding cells [13]. Tumor 
buds are defined as single tumor cells or small cell clusters 
(<5) detached from the main tumor body [14]. In addition 
to nuclear β-catenin and loss of E-cadherin, tumor buds 
are thought to represent a non-proliferating, non-apoptotic 
subgroup of cancer cells derived from the process of EMT 
and highly aggressive in nature as underlined by their 
migratory and invasive immunohistochemical protein 
profile [15]. As a prognostic marker, the presence of high-
grade tumor budding has shown consistent associations 
with negative clinicopathological parameters; it is a 
predictor of lymph node metastasis, distant metastatic 
disease and is a distinctly unfavorable prognostic factor 
in patients with colorectal cancer, independently of 
TNM stage or treatment [14, 16–20]. Furthermore, high-
level DNA microsatellite instability (MSI-H) has been 
associated with more favorable prognosis and little tumor 
budding in colorectal cancer patients [13] as well as with 
decreased EMT marker expression in MSI cell lines 
compared to microsatellite stable (MSS) cells [21].
Although the transcriptional regulation of EMT is 
well-described and WNT-related protein expression changes 
in tumor budding cells are known, only sparse information 
can be found on the possible role of CpG promoter 
methylation on the promotion/suppression of the EMT-like 
phenotype. Since the regulation of E-cadherin is so central 
to the tumor budding process, and given the hypothesis 
of promoter hypermethylation as a possible regulatory 
mechanism for TWIST, we investigate the relationship 
between tumor budding and the CpG methylation status of 
repressors of E-cadherin, TWIST1 and TWIST2.
RESULTS
TWIST1 and TWIST2 methylation patterns in 
colorectal cancer cell lines
We evaluated TWIST1 and TWIST2 methylation 
status in six well-established colorectal cancer cell lines and 
their corresponding immunohistochemistry detection. In all 
cases, cell lines exhibited significant hypermethylation (range 
TWIST1: 52.3%–94.1% and TWIST2: 87.5%–96.8%). 
Immunohistochemistry staining for TWIST1 and TWIST2 
were completely negative in all cell lines (Figure 1).
Figure 1: Pyrosequencing and immunohistochemistry data for TWIST1 and TWIST2 in cell lines showing marked 
hypermethylation across all cell lines and complete negative protein expression (200x magnification, scale bar = 100 μm).
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Correlation of TWIST 1 and TWIST2 with a 
tumor budding phenotype
Of the 215 patients included into cohort 1, 
methylation analysis for TWIST1 was successful in 107 
cases and for TWIST2 in 185 cases. TWIST1 and TWIST2 
CpG methylation was correlated to protein expression 
and tumor budding status. Expression was analyzed by 
tissue microarray in tumor epithelia and tumor stroma, 
separately. Prominent stromal cell staining for TWIST1 
and TWIST2 could be noted with only very infrequent 
expression within tumor epithelia (Figure 2).
Figure 2: Immunohistochemistry of TWIST1 (A, B) and TWIST2 (C, D) on colorectal cancers and (E, F) normal colonic 
tissues. Expression is found almost exclusively in the stroma and ranges from minimal to extensive (200x magnification, scale bar = 100 μm).
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An inverse relationship between methylation 
of TWIST1 and TWIST2 and high-grade budding 
was observed. Of note, all 17 cases considered 
hypermethylated for TWIST1 defined as >75th-percentile 
(>65% methylation) were found to have no or low-grade 
tumor budding (Supplementary Table S1). An inverse 
relationship between higher budding counts and TWIST2 
methylation was also noted ( p = 0.0724) but did not reach 
statistical significance.
In order to better understand the relationship 
between tumor budding, methylation and protein 
expression of TWIST1 and TWIST2, tumor budding status 
was divided into low (≤10 buds/10HPFs on average) and 
high (>10 buds/10 HPFs on average) [14]. In high-grade 
budding cancers, significant inverse correlations between 
TWIST1 methylation and TWIST1 stromal expression 
was observed (high-grade r = –0.4; p < 0.001). Only a 
weak inverse relationship between TWIST2 methylation 
and protein expression was found (ranging from –0.08 to 
–0.11). TWIST1 and TWIST2 expression in stroma were 
significantly positively correlated in low-grade (r = 0.41) 
and to a lesser extent in high-grade (r = 0.26) budding 
cancers.
Laser capture microdissection of low-grade and 
high-grade budding cancers
We selected 1 case with no tumor budding and 
1 case with extensive tumor budding for further analysis. 
TWIST1 and TWIST2 immunohistochemistry were 
performed. In both cases, the tumor epithelium was 
nearly negative with very rare positive cells. In contrast, 
the high-grade budding tumor showed considerable 
stromal cell staining of TWIST1 and TWIST2 while the 
low-grade budding cancers had a mostly negative stroma 
(Figure 3).
We performed laser capture microdissection 
of stroma in both cases. In accordance with the 
immunohistochemistry, we found hypomethylation (3.9% 
and 6.7%, respectively) of TWIST1 and TWIST2 in the 
high-grade budding cancer that stained positive for the 
proteins and a considerable hypermethylation (30.3% and 
42.2%, respectively) of TWIST1 and TWIST2 in the low-
grade budding tumor that stained negative for the proteins 
(Table 1).
We additionally captured 4 different regions of 
tumor epithelium per case (2 tumor center and 2 tumor 
front). Pyrograms can be found in Supplementary 
Figures S1 and S2. In accordance with our results of a 
possible inverse relationship between methylation and 
tumor budding phenotype, we observe a significant 
hypermethylation of TWIST1 and TWIST2 in correlation 
with low-grade budding and a hypomethylation 
of TWIST1 and TWIST2 in the high-grade budding tumor.
Immunohistochemistry for EMT markers in 
low-grade and high-grade budding cases
Whole tissue sections from the same low-grade 
and high-grade budding cancers were immunostained 
for β-catenin, E-cadherin, CDX2 [22], ZEB1 and ZEB2 
and found to exhibit the expected protein phenotype. 
The high-grade budding cancer showed a nuclear 
translocation of β-catenin toward the invasion front, 
loss of membranous E-cadherin, absence of CDX2, 
and increased ZEB1 and ZEB2 in stromal cells at the 
invasion front. The low-grade budding cancer, having 
no buds to analyze, showed the membranous β-catenin, 
intact E-cadherin, nuclear CDX2 and absence of ZEB2 
(Supplementary Figure S3). ZEB1 positive stroma could 
still be observed in this case.
Prognostic significance of TWIST1 and TWIST2 
in colorectal cancer patients
Of the 139 patients originally considered in Cohort 2, 
those receiving a preoperative therapy were excluded from 
the analysis, leaving 112 patients. TWIST1 and TWIST2 
immunohistochemistry was performed on a preoperative 
biopsy tissue microarray of these patients with full 
clinicopathological and overall survival time data. 
Stromal cell staining ranged from minimal to extensive, 
while only rare TWIST1 expression could be found in 
tumor cells. Results are found in Table 2. A significant 
adverse effect of TWIST1 expression was found and 
related to higher tumor grade ( p = 0.0229), more advanced 
pT classification ( p = 0.0044), lymph node metastasis ( p = 
0.0301), lymphatic vessel invasion ( p = 0.0373), frequent 
perineural invasion ( p = 0.0109) and significantly worse 
overall time ( p = 0.0226; Figure 4). This prognostic 
difference was maintained in multivariable analysis 
(Table 3). Although a positive correlation between 
TWIST1 and TWIST2 protein expression was found (r = 
0.64, p < 0.0001), TWIST2 expression was not linked to 
any prognostic features.
TWIST1 and TWIST2 methylation patterns in 
normal colonic tissue and cancer
In order to determine whether the hypermethylation 
of TWIST1 and TWIST2 as a mechanism for TWIST1 
and TWIST2 down-regulation is restricted to tumor, we 
included analysis of 10 normal colonic tissues. TWIST1 
and TWIST2 were significantly more methylated in 
cancers in comparison to normal tissues (TWIST1 
40.9% versus 13%, p = 0.0012, TWIST2 41.4% versus 
21%, p < 0.0001) with a range from 0–100%. Normal 
epithelium was only rarely immunoreactive for either 
protein.
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Figure 3: (Left) High-grade budding and (Right) low-grade budding cancer. (A, B) Pan-cytokeratin staining with designated 
areas subsequently taken for laser capture microdissection including 2 center (blue) and 2 invasion front (red) and (C, D) TWIST1 staining 
showing designated area for subsequent laser capture microdissection of stroma (10x magnification, scale bar = 2000 μm), showing 
(E) positive TWIST1 staining in high-grade budding cancer and (F) negative TWIST1 staining in low-grade budding cancer, (G) TWIST2 
staining in high-grade budding cancer and (H) TWIST2 staining in low-grade budding cancer (200x magnification, scale bar = 100 μm).
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Table 1: Laser capture microdissection results for methylation of TWIST1 and TWIST2 in tumor 
center, front and stroma in a low-grade and high-grade budding cancer
TWIST1 TWIST2
Protein 
expression
Mean 
methylation %
Protein 
expression
Mean 
methylation %
High-grade budding
Center 1 Negative 1.3 Negative 12.8
Center 2 Negative 2.9 Negative 32.8
Front 1 Negative 1.8 Negative 1.3
Front 2 Negative 1.3 Negative 22.8
Stroma Positive 3.9 Positive 6.7
Low-grade budding
Center 1 Negative 84.1 Negative 88.7
Center 2 Negative 22.3 Negative 84.5
Front 1 Negative 97.6 Negative 70.8
Front 2 Negative 1.0 Negative 98.2
Stroma Negative 30.3 Negative 42.2
Table 2: TWIST1 and TWIST2 stromal cell expression and clinicopathological features; median 
values used to define low/high, namely 30% TWIST1 and 50% TWIST2
Feature TWIST1 (n = 113) P-value TWIST2 (n = 115) P-value
Low
(n = 65;
57.5%)
High
(n = 48;
42.5%)
Low
(n = 73;
63.5%)
High
(n = 42;
36.5%)
Gender Male 36 (55.4) 30 (63.8) 0.37 39 (53.4) 30 (73.2) 0.0468
Female 29 (44.6) 17 (36.2) 34 (46.6) 11 (26.8)
Histology Non-mucinous 57 (87.7) 38 (79.2) 0.1049 64 (86.5) 33 (80.5) 0.3197
Mucinous 8 (12.3) 10 (20.8) 10 (13.5) 8 (19.5)
Tumor grade G1-2 50 (79.4) 26 (59.1) 0.0229 50 (71.4) 26 (66.7) 0.604
G3 13 (20.6) 18 (40.9) 20 (28.6) 13 (33.3)
Tumor location Left 18 (27.7) 20 (43.5) 0.2249 16 (21.9) 22 (55.0) 0.0016
Rectum 16 (24.6) 9 (19.6) 20 (27.4) 5 (12.5)
Right 31 (47.7) 17 (37.0) 37 (50.7) 13 (32.5)
pT pT1-2 24 (36.9) 6 (12.8) 0.0044 20 (27.4) 10 (24.4) 0.7264
pT3-4 41 (63.1) 41 (87.3) 53 (72.6) 31 (75.6)
pN pN0 37 (56.9) 17 (36.2) 0.0301 40 (54.8) 18 (43.9) 0.2643
pN1-2 28 (43.1) 30 (63.8) 33 (45.2) 23 (56.1)
cM cM0 45 (72.6) 32 (69.6) 0.7319 24 (77.4) 11 (68.7) 0.5184
cM1 17 (27.4) 14 (30.4) 7 (22.6) 5 (31.3)
L L0 19 (35.9) 7 (16.7) 0.0373 17 (28.3) 10 (27.0) 0.8891
L1-2 34 (64.2) 35 (83.3) 43 (71.7) 27 (73.0)
(Continued )
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Feature TWIST1 (n = 113) P-value TWIST2 (n = 115) P-value
V V0 34 (61.8) 20 (46.5) 0.1306 29 (46.8) 23 (60.5) 0.1815
V1-2 21 (38.2) 23 (53.5) 33 (53.2) 15 (39.5)
Pn Pn0 51 (98.1) 35 (83.3) 0.0109 53 (91.4) 33 (86.8) 0.4767
Pn1 1 (1.9) 7 (16.7) 5 (8.6) 5 (13.2)
MMR status Proficient 47 (82.5) 40 (90.9) 0.2228 56 (82.4) 33 (91.7) 0.1984
Deficient 10 (17.5) 4 (9.1) 12 (17.7) 3 (8.3)
Overall 
survival time 5-year (95%CI)
69.3
(57–79)
38.1
(18–59) 0.0226
63
(51–73)
48
(21–71) 0.8724
TWIST1 stroma low
(n=87,  28 deaths)
TWIST1 stroma high
(n=25,  13 deaths)
Time  (months)
p=0.0226
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Figure 4: Kaplan-Meier curve showing prognostic differences in patients with low or high TWIST1 stromal cell 
expression. Log-rank test.
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DISCUSSION
In this study, we investigated the possible link 
between TWIST1 and TWIST2 methylation in tumor 
epithelium and tumor stroma, the relationship with 
TWIST1 and TWIST2 protein expression and a possible 
role for these genes in promoting a tumor budding 
phenotype. Our results suggest that the pro-tumor effects 
of TWIST1 and, to some degree, TWIST2 come from the 
tumor stroma and that this expression may be regulated at 
least in part by promoter hypermethylation.
A recent work by Laghi and colleagues investigated 
TWIST1 in cell lines and samples of colorectal cancer 
patients [11]. They could show that TWIST1-positive 
cells were predominantly stromal, acquired a fully 
mesenchymal phenotype and appearance, and remarkably, 
showed neoplastic aberrations matching those of the main 
tumor suggesting that an actual EMT had taken place. Our 
findings are in line with these results. Firstly, we show that 
TWIST1 and TWIST2 protein expression are found nearly 
exclusively in the tumor stroma. Selected low- and high-
grade budding cases underlined the extensive expression 
of TWIST1 and TWIST2 in the stromal compartment 
only in the high-grade budding case with matching 
expression of classic hallmarks of EMT in tumor buds 
including nuclear β-catenin, disrupted E-cadherin and 
over-expression of ZEB1 and ZEB2 in stromal cells.
Several studies to date have found that increased 
mRNA expression or protein expression of TWIST1 
correlates to adverse clinicopathological features and 
survival time [11, 23–25]. TWIST1 expression has 
also been quantified in peripheral blood from patients 
with colorectal cancer and shown to correlate not only 
with disease progression but with stem cell marker 
CD133 expression [26]. Strikingly less is known about 
TWIST2, particularly in colorectal cancer. TWIST2 may 
function as a tumor suppressor and has been shown to 
inhibit formation of a microenvironment conducive to 
tumor growth in a murine osteosarcoma model [27]. In 
colorectal cancers, recent results from Yu and colleagues 
suggest that expression of TWIST2 is a valuable adverse 
prognostic marker [28]. In cervical cancers, in comparison 
to TWIST1, TWIST2 may better stratify patients into 
prognostic subgroups and is shown to induce EMT and cell 
motility in cell lines [29]. Also in ovarian cancer TWIST2 
expression is correlated with disease stage [30]. However 
these studies on patient samples differ from ours in that 
immunohistochemistry stains are reported within tumor 
epithelium, rather than tumor stroma. Our findings using a 
well-characterized cohort of 112 patients and preoperative 
cancer biopsies also support an association of TWIST1 
expression and adverse clinicopathological features. Our 
result on biopsy material is novel since these specimens 
do not normally contain the tumor invasion front. Here we 
again observe extensive TWIST1 and TWIST2 staining 
in stromal cells within the main tumor body. However, 
we can confirm associations with more advanced stage of 
disease and survival time only for TWIST1.
Our findings also support a possible role for 
promoter hypermethylation in the regulation of TWIST1 
and to some degree TWIST2. To support this statement, 
the following were performed. First, we assessed 
methylation patterns in 6 well-established colorectal 
cancer cell lines and determined them all to have 
extensive hypermethylation and complete absence of 
protein. Second, we found strong inverse correlations 
between TWIST1 methylation and stromal expression 
of TWIST1 protein in our patient samples. Thirdly, 
we performed laser capture microdissection to dissect 
out tumor epithelium from tumor stroma in regions 
previously stained for TWIST1 and TWIST2 protein. The 
concordance between stromal expression and methylation 
status could be confirmed. Other groups have reported on 
TWIST1 and TWIST2 methylation in colorectal cancer. 
Celesti and colleagues treated HCT116 cells with a DNA 
methyltransferase inhibitor. Restoration of TWIST1 
RNA and protein could be seen, indicating that promoter 
methylation may at least to some degree be responsible 
for the absence of TWIST protein. Hypermethylation 
in cancers in comparison to normal tissues is observed 
Table 3: Multivariable survival analysis of TWIST1 protein expression in stroma
Feature HR (95%CI) P-value
Stroma Low 1.0 0.0467
High 1.99 (1.01–3.92)
pT pT1-2 1.0 0.8425
pT3-4 0.92 (0.4–2.1)
pN pN0 1.0 0.8075
pN1-2 1.09 (0.55–2.2)
Therapy None 1.0 0.0589
Treated 0.4 (0.2–1.04)
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for TWIST1 [25]. Moreover, Ashktorab and colleagues, 
performing an extensive bioinformatics work on CpG 
island Methylator Phenotype, identified TWIST1 as 
markedly hypermethylated in colorectal cancer [31]. Other 
groups report methylation percentages of >40% across 
these tumors [32, 33]. Our results confirm these findings 
not only for TWIST1 but also TWIST2. Methylation as a 
regulatory mechanism for TWIST1 could be confirmed by 
Okada et al on cell lines, but not in patient samples [25]. 
We hypothesize that discrepancies between methylation 
and expression among patient samples of colorectal cancer 
may be due to location of TWIST1 stained cells, namely in 
the tumor stroma, rather than tumor epithelium.
There are many studies that have identified several 
pathways that control Twist1 expression in tumors, which 
include NF-κB and STAT3 mediated cytokine signaling 
[34, 35], induction through hypoxia-inducible factor 1α 
[36] and the TGFβ pathway [37, 38] as well as post-
transcriptional regulatory mechanism by miRNAs [12, 
39] but in normal colorectal mucosa these mechanisms 
are unknown. We observed lack of correlation between 
hypermethylation and protein expression in normal 
colorectal mucosa may suggest that hypermethylation as 
a regulatory mechanism of TWIST1 and TWIST2 may be 
restricted to the tumor microenvironment. These results 
are supported by others [25, 33]. Other mechanisms of 
TWIST1 regulation in normal tissue may include post-
translational histone modifications, however this aspect 
still remains to be elucidated. Nonetheless, in normal 
colorectal mucosa hypermethylation seems not to be 
implicated in the Twist1 regulation.
This study is novel for several reasons. 1) To 
our knowledge, this may be the first study to perform 
methylation analysis from stromal tissue. We further 
underline here the feasibility of such an analysis. 2) We 
perform an extensive evaluation of TWIST1 and TWIST2 
hypermethylation and corresponding protein expression 
on normal colonic tissues, established cell lines, a large 
number of human colorectal cancer specimens. 3) We show 
that extensive tumor budding may take place in the context 
of a TWIST1 (and TWIST2) positive stroma and that such 
a stroma demonstrates hallmarks of EMT. 4) We perform 
TWIST1 and TWIST2 evaluations on preoperative biopsy 
material and are able to underline the prognostic effect of 
TWIST1, even within the main tumor body.
This study may also have several limitations. 
Although the correlation between TWIST1 methylation 
and protein expression is strong, the same is not true for 
TWIST2. This may be due to the wide range of possible 
sequences to target during CpG analysis. Secondly, no 
methylation analysis was performed on Cohort 2. The 
aim of this second cohort was however to investigate the 
prognostic effect of the proteins rather than determine 
correlations with methylation. Since patients with mismatch 
repair deficient (i.e, MSI-H) colon cancers typically exhibit 
little tumor budding, one would expect an association 
between MMR-deficiency and low TWIST expression. 
Although our results do not reach statistical significance 
possibly due to the relatively low number of cases in this 
series, 10/14 MMR-deficient cancers were low for TWIST1 
while 12/15 deficient cases were low for TWIST2.
Questions remain as to the timing and mechanism 
of action at the tumor/stroma interface. Presumably, the 
most favorable (possibly default) state for the tumor is 
one in which TWIST1 and TWIST2 are not prevented 
from being expressed, thus allowing these genes to exert 
their functions and facilitating and progression. A role 
for hypermethylation in counteracting the formation of 
tumor budding would suggest this to be an early event 
in tumorigenesis, a hypothesis which remains to be 
determined.
The results of this study suggest that TWIST1 and 
to a lesser degree TWIST2 expressed within the tumor 
stroma could contribute to the EMT-like tumor budding 
phenotype in colorectal cancers. Our evidence suggests a 
possible role for promoter methylation as a mechanism of 
TWIST1 regulation.
METHODS
Patients
Two retrospective colorectal cancer patient cohorts 
were entered into this study. Cohort 1 included 215 non-
consecutive patients treated at the Fourth Department of 
Surgery, University of Athens Medical School in Athens, 
Greece, between 2002 and 2007. Cohort 2 included 139 
non-consecutive patients treated at the Insel Hospital, Bern, 
Switzerland between 2002 and 2011. Detailed information 
on both cohorts can be found in Supplementary Table S2. 
Patient gender, age at diagnosis, tumor location, post-
operative and pre-operative therapy and overall survival 
time were obtained from patient records. All cases were 
re-reviewed on H&E stained slides by expert gastro-intestinal 
pathologists. Features included the pT, pN, pM, tumor grade, 
histological subtype, venous invasion, perineural invasion 
(Pn) and lymphatic invasion. For all cases, mismatch repair 
(MMR) status was determined by evaluating the proteins 
MLH1, MSH2 and MSH6 (Cohort 1) and additionally 
PMS2 (Cohort 2). Tumor budding was evaluated using 
the 10-hotspot method [14]. Briefly, pan-cytokeratin 
immunohistochemistry (AE1/AE3) was performed on whole 
tissue sections from each case. The slide was scanned at low-
magnification and the 10 densest regions of tumor budding 
were identified and counted using high-power fields. The 
average number of buds across these 10 fields was recorded.
Specimen characteristics
Tumors from both Cohorts 1 and 2 were fixed 
in 10% buffered formalin and embedded in paraffin. 
Representative tumor blocks from all cases were retrieved 
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from the corresponding institutes of pathology and 
used for tissue microarray construction and molecular 
analysis. In addition, 10 normal colonic tissue blocks 
were identified in order to obtain baseline comparisons 
for methylation analysis.
Tissue microarray construction
Tissue microarray construction was performed using 
a next-generation Tissue Micro Array (ngTMA) approach 
[40]. Briefly, an H&E slide from 1 representative tumor 
block per case was freshly sectioned and scanned using 
a Pannoramic P250 scanner (3DHistech, Hungary). Next, 
digital slides were annotated using a TMA tool (Pannoramic 
Viewer, 3DHistech, Hungary). For cohort 1, the digital 
slides of each surgical resection were annotated using a 
0.6mm tool as follows: 3 annotations of tumor center, 3 of 
tumor front, and 3 of tumor buds, wherever possible. For 
cohort 2, preoperative biopsy material from each case was 
annotated using a 1mm TMA tool. These characteristics 
are summarized in Supplementary Table S2. Next, 
annotated regions were punched out using an automated 
tissue microarray and transferred into corresponding 
recipient ngTMA blocks (TMA Grandmaster, 3DHistech, 
Hungary). Ethics committee approval was obtained from 
the University of Athens (cohort 1) and Insel Hospital 
(cohort 2, Registration number 07-10-13).
Immunohistochemistry
Both ngTMAs for Cohorts 1 and 2 were 
immunostained for TWIST1 and TWIST2 using an 
automated Leica Bond Rx instrument with the following 
conditions and antibodies: TWIST1, pre-treatment in 
citrate buffer at 100°C for 30 minutes, Abcam, rabbit 
polyclonal, dilution 1:25; TWIST2, pre-treatment with Tris 
buffer at 95° for 30 minutes, Abcam mouse monoclonal, 
clone 2C1a, dilution 1:75. Counterstaining was performed 
with hematoxylin.
Additionally, selected cases underwent 
immunohistochemistry for markers known to be involved in 
EMT, namely β-catenin (Abcam, clone E247, pre-treatment 
in Tris buffer, 95°C for 30 minutes, 1:500), E-cadherin 
(Dako, clone NCH38, pre-treatment in Tris buffer, 95°C 
for 30 minutes, 1:200), CDX2 (Novocastra, AMT28, pre-
treatment in Tris buffer 95°C for 30 minutes, 1:200), ZEB1 
(Sigma-Aldrich, pre-treatment in citrate buffer 100°C for 20 
minutes, 1:600) and ZEB2 (Sigma-Aldrich, pre-treatment in 
Tris buffer 95°C for 60 minutes, 1:100).
Methylation analysis
From all cases in cohort 1 and 10 cases of healthy 
tissues performed in parallel, DNA was extracted. For 
tumors, this was performed by marking the corresponding 
H&E slides in areas of invasive cancer. A minimum of 
five whole tissue sections from each case were cut from 
corresponding paraffin-embedded tissue blocks at 4μm. 
Slides were scratched using a scalpel in designated 
regions. DNA was extracted using standard protocols 
(QIAamp® DNA FFPE Tissue, Qiagen). Bisulfite 
conversion for subsequent methylation analysis was 
undertaken (EpiTect® Bisulfite Conversion Kit, Qiagen). 
PCR was performed using the Pyromark PCR kit (Qiagen) 
with the following primer sequences for TWIST1 (Entrez 
Gene ID: 7291) (Microsynth): Forward (biotinylated) 
5′-GAAGTTGGAGGGTTGAGG-3′, Reverse 5′- 
AACTAAACACC TCCTACATCATCT CT-3′ and 
Sequencing 5′- ACACCTCCTAC ATCATCTCTC-3′. 
The PCR conditions were as follows: activation step at 
95°C for 15 min, denaturation 30 sec at 94°C , annealing 
42 cycles of 30 sec at 56°C, and extension 30 seconds at 
72°C and final extension 10 min at 72°C. The sequence 
to analyze was RAACRACRAC RCRTAACCTC 
RCRAACCCRA AACAAAAAAA AAAAAC and 
contained 8 CpG sites. The region is located on 
chromosome 7 at region 19156483-19157779. For 
TWIST2 (Entrez Gene ID: 117581), a CpG assay from 
Qiagen was tested (TWIST2_01, sequence to analyze: 
YGGYGYGTT GATTGGTYGYGGT GGTYGGGGGT) 
with 6 CpG sites. The region of interest is found within 
the CpG island located on chromosome 2 at 239 756 376-
239 758 300. After PCR, fragment analysis was carried 
out using a Qiaxcel system (Qiagen). Pyrosequencing was 
performed using a PyroMark Q24. Bisulfite controls were 
included into the pyrogram for each assay manually to 
ensure complete conversion of DNA. In addition, a control 
oligo and water control was used in every pyrosequencing 
run as well as appropriate methylated and unmethylated 
controls (Epitec® PCR Control DNA; Qiagen).
Colorectal cancer cell lines
In addition to colorectal cancer tissues, six 
well-established human colon cancer cell lines were 
included in this study (HCT15, SW620, LS180, 
HCT116, COLO205, and HT29). Cells were grown in 
DMEM (HT29), RPMI-1640 (HCT15, SW620, and 
Colo205), McCoy’s (HCT116), or EMEM (LS180) cell 
culture medium (Sigma-Aldrich, Buchs, Switzerland) 
supplemented with 10% fetal bovine serum, L-Glutamine 
and Non-Essential Amino Acids (Sigma-Aldrich) at 37°C 
in a 5% CO2 humified atmosphere. No Antibiotics were 
used. Genomic DNA was extracted (DNeasy Blood & 
Tissue Kit, Qiagen) and pyrosequencing for TWIST1 
and TWIST2 was undertaken as mentioned above. 
Cell line pellets were fixed, paraffin-embedded and 
immunohistochemistry for TWIST1 and TWIST2 was 
carried out.
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Laser capture microdissection of low and 
high-grade budding case
In order to analyze areas of tumor stroma and tumor 
epithelium separately and precisely, 2 colorectal cancers 
were selected from cohort 2 known to represent a no/low-
grade tumor budding case and a high-grade budding case 
after pan-cytokeratin staining of whole tissue sections. Next, 
these cases underwent immunohistochemistry for TWIST1 
and TWIST2 followed by laser capture microdissection 
(Zeiss). Briefly, 5x5um sections were cut and placed onto 
irradiated PEN-membrane slides (Zeiss). Laser capture 
was performed using a PALMRobo V4.2. DNA extraction 
(QIAmp DNA Micro Kit, Qiagen), bisulfite conversion, 
PCR and pyrosequencing for TWIST1 and TWIST2 was 
performed on 2 areas of tumor center, 2 areas of invasion 
front and 1 large area of tumor stroma for each case.
Statistical analysis
Descriptive statistics using means, median and 
quartiles were performed. Correlation between ranked 
variables was analyzed using Spearman’s correlation 
coefficient (r). Chi-Square or Fisher’s Exact tests were 
used to analyze categorical variables. The non-parametric 
Wilcoxon Rank Sum or Kruskal-Wallis tests were used 
for continuous variables. Kaplan-Meier curves and log-
rank tests were applied to detect overall survival time 
differences. After verifying the proportional hazards 
assumption, Cox regression analysis for multivariable 
survival time analysis was performed. P-values <0.05 
were considered statistically significant. All analyses were 
carried out using SAS V9.2 (the SAS Institute, Cary, NC).
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